Nicholas A. Vitanza

Jan 7, 2025 | nature.com | Nicholas A. Vitanza |Michelle Choe |wenjun Huang |Madison Beam |ashley wilson |Erin E. Crotty | +6 more

AbstractDiffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical trial of repetitive intracerebroventricular (ICV) dosing of B7-H3-targeting chimeric antigen receptor T cells (B7-H3 CAR T cells) for children with recurrent or refractory CNS tumors and DIPG.

Sep 2, 2024 | nature.com | Edward Lee |Michelle Han |Hollie A. Lai |Kristian Aquilina |Tina Y Poussaint |Vijay Ramaswamy | +6 more

AbstractWhile multiple factors impact disease, artificial intelligence (AI) studies in medicine often use small, non-diverse patient cohorts due to data sharing and privacy issues. Federated learning (FL) has emerged as a solution, enabling training across hospitals without direct data sharing. Here, we present FL-PedBrain, an FL platform for pediatric posterior fossa brain tumors, and evaluate its performance on a diverse, realistic, multi-center cohort.

Sep 1, 2024 | flipboard.com | Edward Lee |Michelle Han |Jason Wright |Michael S. Kuwabara |Olivia Choudhury |Ujjwal Ratan | +36 more

The Arctic2 hours agoTwo Cybertrucks Drove from Florida to the Arctic Circle and It Looks Like a NightmareGizmodo - Matthew Gault • 2hThe journey is an endurance test for the embattled electric vehicle that reveals a lot about North America's shoddy charging infrastructure.

Aug 2, 2023 | cell.com | Bryce Thomas |Michelle Monje |Nicholas A. Vitanza |Alicia M. Douglas

HighlightsThe lack of effective therapies for DMG stems from tumor location, complex molecular features, and immunosuppressive tumor immune microenvironment. CAR therapy can effectively elicit an immune response in immunologically cold diffuse midline glioma tumors. Locoregional infusions of CAR T cells minimize therapy related toxicities, promote proinflammatory immune engagement, and may reduce immunosuppressive responses.

Apr 6, 2023 | nature.com | Karin Straathof |Tom Davidson |Kara L. Davis |Juliane Gust |Michael Lim |Robbie G. Majzner | +6 more

AbstractCancer immunotherapies have unique toxicities. Establishment of grading scales and standardized grade-based treatment algorithms for toxicity syndromes can improve the safety of these treatments, as observed for cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) in patients with B cell malignancies treated with chimeric antigen receptor (CAR) T cell therapy.